13.00
-0.33(-2.48%)
Currency In USD
| Previous Close | 13.33 |
| Open | 13.14 |
| Day High | 13.45 |
| Day Low | 12.93 |
| 52-Week High | 61.9 |
| 52-Week Low | 5.25 |
| Volume | 397,530 |
| Average Volume | 485,563 |
| Market Cap | 158.33M |
| PE | -2.76 |
| EPS | -4.71 |
| Moving Average 50 Days | 16.97 |
| Moving Average 200 Days | 37.78 |
| Change | -0.33 |
If you invested $1000 in Corbus Pharmaceuticals Holdings, Inc. (CRBP) 10 years ago, it would be worth $144.44 as of December 21, 2024 at a share price of $13. Whereas If you bought $1000 worth of Corbus Pharmaceuticals Holdings, Inc. (CRBP) shares 5 years ago, it would be worth $79.37 as of December 21, 2024 at a share price of $13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors
GlobeNewswire Inc.
Dec 09, 2024 12:00 PM GMT
CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environmentNORWOOD, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”)
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
GlobeNewswire Inc.
Dec 03, 2024 12:00 PM GMT
NORWOOD, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that the U.S. Food and Drug Administra
Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference
GlobeNewswire Inc.
Nov 21, 2024 1:00 PM GMT
NORWOOD, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and